Distinguishing Lewy body dementias from Alzheimer’s disease
- 1 November 2007
- journal article
- research article
- Published by Taylor & Francis Ltd in Expert Review of Neurotherapeutics
- Vol. 7 (11), 1499-1516
- https://doi.org/10.1586/14737175.7.11.1499
Abstract
Lewy body dementia (LBD) is the second most common dementia after Alzheimer's disease (AD). LBD is characterized clinically by visual hallucinations, extrapyramidal symptoms, cognitive fluctuations and neuroleptic sensitivity. LBD and AD share many common features in pathology, genetics and biochemical alterations; however, correct clinical distinction between these disorders has prognostic and therapeutic implications. There are currently no definitive radiological or biological markers for LBD, but studies suggest that premorbid differences in cognitive domains and personality traits, differences in clinical presentation, and alterations in autonomic function and sleep may improve diagnosis. Cholinergic dysfunction plays a major role in both AD and LBD; however, dysfunction is greater in LBD. This may account for the more prominent hallucinations, and offers the possibility of a greater response to cholinesterase inhibitors in LBD. The treatment of LBD is symptomatic and is based on a limited number of clinical trials and extension of results from trials in AD. Current research is focused on the role of synuclein aggregation with possible roles for synuclein-derived peptides as aggregation inhibitors. Other approaches target amyloid, neuroinflammation, oxidative injury, proteolysis, lipid peroxidation and immunotherapies with variable results. Improved understanding of disease mechanisms may open new therapeutic avenues for LBD in the future.Keywords
This publication has 100 references indexed in Scilit:
- Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementiasMolecular Psychiatry, 2007
- Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's diseaseProceedings of the National Academy of Sciences of the United States of America, 2006
- The Progression of Cognition, Psychiatric Symptoms, and Functional Abilities in Dementia With Lewy Bodies and Alzheimer DiseaseArchives of Neurology, 2006
- Nonviral Aβ DNA vaccine therapy against Alzheimer’s disease: Long-term effects and safetyProceedings of the National Academy of Sciences of the United States of America, 2006
- What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?Brain, 2006
- The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementiaAnnals of Neurology, 2003
- α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodiesProceedings of the National Academy of Sciences of the United States of America, 1998
- AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's diseaseNature Genetics, 1998
- Clinical course of patients with idiopathic Parkinson's diseaseMovement Disorders, 1996
- LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted β-amyloid precursor protein and mediates its degradationCell, 1995